These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

90 related items for PubMed ID: 20089400

  • 1. Synthesis and discovery of 2,3-dihydro-3,8-diphenylbenzo[1,4]oxazines as a novel class of potent cholesteryl ester transfer protein inhibitors.
    Wang A, Prouty CP, Pelton PD, Yong M, Demarest KT, Murray WV, Kuo GH.
    Bioorg Med Chem Lett; 2010 Feb 15; 20(4):1432-5. PubMed ID: 20089400
    [Abstract] [Full Text] [Related]

  • 2. Design, synthesis, and biological evaluation of (2R,alphaS)-3,4-dihydro-2-[3-(1,1,2,2-tetrafluoroethoxy)phenyl]-5-[3-(trifluoromethoxy)-phenyl]-alpha-(trifluoromethyl)-1(2H)-quinolineethanol as potent and orally active cholesteryl ester transfer protein inhibitor.
    Kuo GH, Rano T, Pelton P, Demarest KT, Gibbs AC, Murray WV, Damiano BP, Connelly MA.
    J Med Chem; 2009 Mar 26; 52(6):1768-72. PubMed ID: 19236017
    [Abstract] [Full Text] [Related]

  • 3. Chromanol derivatives--a novel class of CETP inhibitors.
    Vakalopoulos A, Schmeck C, Thutewohl M, Li V, Bischoff H, Lustig K, Weber O, Paulsen H, Elias H.
    Bioorg Med Chem Lett; 2011 Jan 01; 21(1):488-91. PubMed ID: 21084191
    [Abstract] [Full Text] [Related]

  • 4. Tetrazole and ester substituted tetrahydoquinoxalines as potent cholesteryl ester transfer protein inhibitors.
    Eary CT, Jones ZS, Groneberg RD, Burgess LE, Mareska DA, Drew MD, Blake JF, Laird ER, Balachari D, O'Sullivan M, Allen A, Marsh V.
    Bioorg Med Chem Lett; 2007 May 01; 17(9):2608-13. PubMed ID: 17331716
    [Abstract] [Full Text] [Related]

  • 5. Design and synthesis of potent inhibitors of cholesteryl ester transfer protein (CETP) exploiting a 1,2,3,4-tetrahydroquinoline platform.
    Rano TA, Sieber-McMaster E, Pelton PD, Yang M, Demarest KT, Kuo GH.
    Bioorg Med Chem Lett; 2009 May 01; 19(9):2456-60. PubMed ID: 19339179
    [Abstract] [Full Text] [Related]

  • 6. Discovery of novel benzoxazinones as potent and orally active long chain fatty acid elongase 6 inhibitors.
    Mizutani T, Ishikawa S, Nagase T, Takahashi H, Fujimura T, Sasaki T, Nagumo A, Shimamura K, Miyamoto Y, Kitazawa H, Kanesaka M, Yoshimoto R, Aragane K, Tokita S, Sato N.
    J Med Chem; 2009 Nov 26; 52(22):7289-300. PubMed ID: 19883081
    [Abstract] [Full Text] [Related]

  • 7. Discovery of a simple picomolar inhibitor of cholesteryl ester transfer protein.
    Reinhard EJ, Wang JL, Durley RC, Fobian YM, Grapperhaus ML, Hickory BS, Massa MA, Norton MB, Promo MA, Tollefson MB, Vernier WF, Connolly DT, Witherbee BJ, Melton MA, Regina KJ, Smith ME, Sikorski JA.
    J Med Chem; 2003 May 22; 46(11):2152-68. PubMed ID: 12747787
    [Abstract] [Full Text] [Related]

  • 8. Design and synthesis of new tetrahydroquinolines derivatives as CETP inhibitors.
    Escribano A, Mateo AI, Martin de la Nava EM, Mayhugh DR, Cockerham SL, Beyer TP, Schmidt RJ, Cao G, Zhang Y, Jones TM, Borel AG, Sweetana SA, Cannady EA, Mantlo NB.
    Bioorg Med Chem Lett; 2012 Jun 01; 22(11):3671-5. PubMed ID: 22543028
    [Abstract] [Full Text] [Related]

  • 9. Diphenylpyridylethanamine (DPPE) derivatives as cholesteryl ester transfer protein (CETP) inhibitors.
    Harikrishnan LS, Finlay HJ, Qiao JX, Kamau MG, Jiang J, Wang TC, Li J, Cooper CB, Poss MA, Adam LP, Taylor DS, Chen AY, Yin X, Sleph PG, Yang RZ, Sitkoff DF, Galella MA, Nirschl DS, Van Kirk K, Miller AV, Huang CS, Chang M, Chen XQ, Salvati ME, Wexler RR, Lawrence RM.
    J Med Chem; 2012 Jul 12; 55(13):6162-75. PubMed ID: 22650305
    [Abstract] [Full Text] [Related]

  • 10. Novel tetrahydrochinoline derived CETP inhibitors.
    Schmeck C, Gielen-Haertwig H, Vakalopoulos A, Bischoff H, Li V, Wirtz G, Weber O.
    Bioorg Med Chem Lett; 2010 Mar 01; 20(5):1740-3. PubMed ID: 20137927
    [Abstract] [Full Text] [Related]

  • 11. 2-Arylbenzoxazoles as CETP inhibitors: raising HDL-C in cynoCETP transgenic mice.
    Kallashi F, Kim D, Kowalchick J, Park YJ, Hunt JA, Ali A, Smith CJ, Hammond ML, Pivnichny JV, Tong X, Xu SS, Anderson MS, Chen Y, Eveland SS, Guo Q, Hyland SA, Milot DP, Cumiskey AM, Latham M, Peterson LB, Rosa R, Sparrow CP, Wright SD, Sinclair PJ.
    Bioorg Med Chem Lett; 2011 Jan 01; 21(1):558-61. PubMed ID: 21094047
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. 2-(4-carbonylphenyl)benzoxazole inhibitors of CETP: scaffold design and advancement in HDLc-raising efficacy.
    Sweis RF, Hunt JA, Kallashi F, Hammond ML, Chen Y, Eveland SS, Guo Q, Hyland SA, Milot DP, Cumiskey AM, Latham M, Rosa R, Peterson L, Sparrow CP, Wright SD, Anderson MS, Sinclair PJ.
    Bioorg Med Chem Lett; 2011 Mar 15; 21(6):1890-5. PubMed ID: 21147531
    [Abstract] [Full Text] [Related]

  • 14. Design of a novel class of biphenyl CETP inhibitors.
    Lu Z, Napolitano JB, Theberge A, Ali A, Hammond ML, Tan E, Tong X, Xu SS, Latham MJ, Peterson LB, Anderson MS, Eveland SS, Guo Q, Hyland SA, Milot DP, Chen Y, Sparrow CP, Wright SD, Sinclair PJ.
    Bioorg Med Chem Lett; 2010 Dec 15; 20(24):7469-72. PubMed ID: 21041082
    [Abstract] [Full Text] [Related]

  • 15. Triphenylethanamine Derivatives as Cholesteryl Ester Transfer Protein Inhibitors: Discovery of N-[(1R)-1-(3-Cyclopropoxy-4-fluorophenyl)-1-[3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl]-2-phenylethyl]-4-fluoro-3-(trifluoromethyl)benzamide (BMS-795311).
    Qiao JX, Wang TC, Adam LP, Chen AY, Taylor DS, Yang RZ, Zhuang S, Sleph PG, Li JP, Li D, Yin X, Chang M, Chen XQ, Shen H, Li J, Smith D, Wu DR, Leith L, Harikrishnan LS, Kamau MG, Miller MM, Bilder D, Rampulla R, Li YX, Xu C, Lawrence RM, Poss MA, Levesque P, Gordon DA, Huang CS, Finlay HJ, Wexler RR, Salvati ME.
    J Med Chem; 2015 Nov 25; 58(22):9010-26. PubMed ID: 26524347
    [Abstract] [Full Text] [Related]

  • 16. Thyroid hormone increases plasma cholesteryl ester transfer protein activity and plasma high-density lipoprotein removal rate in transgenic mice.
    Berti JA, Amaral ME, Boschero AC, Nunes VS, Harada LM, Castilho LN, Oliveira HC.
    Metabolism; 2001 May 25; 50(5):530-6. PubMed ID: 11319713
    [Abstract] [Full Text] [Related]

  • 17. Cholesteryl ester transfer protein promotes the formation of cholesterol-rich remnant like lipoprotein particles in human plasma.
    Okamoto H, Miyai A, Sasase T, Furukawa N, Matsushita M, Nakano T, Nakajima K.
    Clin Chim Acta; 2007 Jan 25; 375(1-2):92-8. PubMed ID: 16859664
    [Abstract] [Full Text] [Related]

  • 18. Biphenyl-substituted oxazolidinones as cholesteryl ester transfer protein inhibitors: modifications of the oxazolidinone ring leading to the discovery of anacetrapib.
    Smith CJ, Ali A, Hammond ML, Li H, Lu Z, Napolitano J, Taylor GE, Thompson CF, Anderson MS, Chen Y, Eveland SS, Guo Q, Hyland SA, Milot DP, Sparrow CP, Wright SD, Cumiskey AM, Latham M, Peterson LB, Rosa R, Pivnichny JV, Tong X, Xu SS, Sinclair PJ.
    J Med Chem; 2011 Jul 14; 54(13):4880-95. PubMed ID: 21682257
    [Abstract] [Full Text] [Related]

  • 19. Novel 2,3-dihydro-1,4-benzoxazines as potent and orally bioavailable inhibitors of tumor-driven angiogenesis.
    La DS, Belzile J, Bready JV, Coxon A, DeMelfi T, Doerr N, Estrada J, Flynn JC, Flynn SR, Graceffa RF, Harriman SP, Larrow JF, Long AM, Martin MW, Morrison MJ, Patel VF, Roveto PM, Wang L, Weiss MM, Whittington DA, Teffera Y, Zhao Z, Polverino AJ, Harmange JC.
    J Med Chem; 2008 Mar 27; 51(6):1695-705. PubMed ID: 18311900
    [Abstract] [Full Text] [Related]

  • 20. 2D Quantitative structure-activity relationship studies on a series of cholesteryl ester transfer protein inhibitors.
    Castilho MS, Guido RV, Andricopulo AD.
    Bioorg Med Chem; 2007 Sep 15; 15(18):6242-52. PubMed ID: 17604633
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.